ClinicalTrials.gg
CompletedNCT00356915Updated Feb 9, 2017Results posted

Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.

A Phase 3 interventional study of Itraconazole 100mg capsules and Itraconazole 200mg tablets in Onychomycosis, sponsored by Stiefel, a GSK Company. Completed at 68 sites in 7 countries. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-02-09.

Sponsored by Stiefel, a GSK Company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,381
Allocation
Randomized
Ages
16 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies in Onychomycosis with a site in United States — 3 open to participants now, 7 under way, 1 of them phase 3. Onychomycosis · United States.

Enrollment
Largest of 75
1,381 · median 50
Started
2006
with 6 others
Phase 3
14 of 77
none open now
Registered
3rd of 77
by date
Lead sponsor
4 of 77
Stiefel, a GSK Company

Among the 77 studies in Onychomycosis with a site in United States, this one has the largest enrollment of the 75 interventional ones that give a count, is one of 7 that started in 2006, is one of 14 in phase 3, and was the 3rd registered.

Onychomycosis

158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.

Browse Onychomycosis studies →

Open to participants now

3 of the 77 studies in Onychomycosis with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 16 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Onychomycosis with a site in United States, or all of them as a file.
02

Study summary

Onychomycosis is a common condition accounting for approximately half of all nail disorders. It is most commonly caused by dermatophytes. Itraconazole has been approved for the treatment of onychomycosis in the United States with an approved dosage regimen for the treatment of onychomycosis of the toenail of once daily (QD) treatment with 200mg of itraconazole (two 100 mg capsules) for 12 weeks. Barrier Therapeutics has developed a 200 mg tablet which could be used in a more convenient one-tablet-per-day dosing regimen. This clinical trial will compare the efficacy and safety of this new tablet formulation with itraconazole capsules and placebo.

Read the detailed description

Onychomycosis is common and accounts for about half of all nail disorders. Usually the cause is due to dermatophytes, either Trichophyton rubrum (71%) or Trichophyton mentagrophytes (20%) but may also be due to yeast infection, usually Candida albicans.

The prevalence of onychomycosis in the United States population as a whole is 13% and is more prevalent in the elderly (60%). Onychomycosis of the toenail recurs and is thought to have a genetic component.

Onychomycosis can result in permanent nail deformity. This disease has a significant impact on the patient's quality of life (e.g., concern with the appearance of the toenails and fingernails, interference with wearing shoes, walking and sports activities).

Itraconazole has been approved for the treatment of onychomycosis in the United States since the mid-nineteen-nineties. The approved dosage regimen for treatment of onychomycosis of the toenail is once daily (QD) treatment with 200 mg of itraconazole (Sporanox®, Janssen Pharmaceutical Products, L.P., Titusville, NJ, USA) for 12 weeks. The approved dosage form is a 100mg capsule. Barrier Therapeutics has developed a 200mg tablet which could be used in a more convenient one-tablet-per-day dosing regimen.

This clinical trial will compare the efficacy and safety of this new tablet formulation with itraconazole capsules and placebo.

03

Conditions studied

  • Onychomycosis

Browse trials for

Keywords

  • Nail fungus
  • Onychomycosis
  • Itraconazole
  • Toenail
04

Who can participate

Ages eligible
16 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of onychomycosis of at least one great toenail
  • Percent Nail Involvement Score of the more severely affected great toenail (the Target Toenail) must be between 2 and 3 (25-75% of the nail unit).
  • Length of Unaffected Part of the Target Toenail ≥2mm
  • Direct microscopic examination with KOH that is positive for the hyphae associated with dermatophytes on the target toenail
  • Subjects must have signed
  • If the subject is woman of , she must have a negative urine pregnancy test and agree to use an effective form of until the first menses after 60 days following the last dose of study medication.

Exclusion criteria

Exclusion Criteria:

  • Onychomycosis caused by Candida spp. without the presence of a dermatophyte
  • Participation in a clinical trial for the systemic treatment of onychomycosis of the toenail within 24 weeks prior to Visit 1
  • Use of systemic antifungals within 12 weeks prior to Visit 1
  • Use of topical antifungal nail lacquer within 30 days prior to Visit 1
  • Use of any other topical onychomycosis treatment on any toenail within 7 days prior to Visit 1
  • Evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF
  • Known liver disease or a history of liver toxicity with other drugs
  • Use of systemic
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
1,381 participants (actual)

Study arms

  • Experimental
    Itraconazole tablets

    Itraconazole 200 mg tablets

    Drug: Itraconazole 200mg tablets

  • Active comparator
    Itraconazole capsules

    Two Itraconazole 100 mg capsules were taken daily.

    Drug: Itraconazole 100mg capsules

  • Placebo comparator
    Placebo tablets

    The itraconazole 200-mg tablets and placebo tablets exactly matched one another and were white to slightly grey in color, were oblong and biconvex in shape, and were melt-extrusion, film-coated.

    Drug: Placebo tablets

Interventions

  • Subjects took two 100mg capsules once per day after a full meal. The dose dose was taken the day before the Week 12 visit.

    Also known as: Sporanox®

  • Subjects took one 200mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.

    Also known as: Onmel

  • DrugPlacebo tablets

    Placebo tablets are the same as the Itraconazole tablets but without the active drug included. Subjects took one tablet once per day after a full meal. The last tablet was taken the day before the Week 12 visit.

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. Clinical and Mycological Cure of Target Toenail

    This study was designed to evaluate the superiority of itraconazole tablets to placebo tablets. Clinical Cure was defined as an IGA score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) exam and a negative culture for dermatophytes of the target toenail.

    Time frame: 1 year

  2. Complete Cure - Itraconazole Tablets Compared to Itraconazole Capsules

    The primary efficacy endpoint was Compete Cure (consisting of a Clinical Cure and a Mycological Cure) at week 52. In this study, Clinical Cure was defined as an Investigator's Global Assessment (IGA) score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) examination and a negative culture outcome for dermatophytes of the target toenail. The efficacy analyses were conducted to demonstrate the non-inferiority of 1 itraconazole 200-mg tablet to 2 itraconazole 100-mg capsule.

    Time frame: 12 months

Secondary outcomes

  1. Clinical Improvement of the Target Toenail

    Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52. The Investigator's Global Assessment (IGA) assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement. 0 = Clinical Cure: No evidence of onychomycosis. 1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: \>50% dystrophy with onycholysis.

    Time frame: 12 months

  2. Clinical Improvement Compared to Placebo

    Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52. The Investigator's Global Assessment(IGA)assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement. 0 = Clinical Cure: No evidence of onychomycosis. 1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: \>50% dystrophy with onycholysis.

    Time frame: 12 months

07

Results

Posted Jan 4, 2012

Participant flow

Subjects were recruited from clinics in the US, Canada, South America, Ecuador, Dominican Republic, Panama, and Honduras.

Participant flow — Overall Study
MilestoneItraconazole TabletsItraconazole CapsulesPlacebo Tablets
Started593590198
Completed517496156
Not completed769442
Withdrew: Non compliance121
Withdrew: Protocol violation232
Withdrew: Withdrawal by subject141410
Withdrew: Lack of efficacy003
Withdrew: Lost to follow-up273414
Withdrew: Administrative decision001
Withdrew: Physician decision020
Withdrew: Adverse event21318
Withdrew: Miscellaneous reasons1183

Outcome measures

PrimaryClinical and Mycological Cure of Target Toenail

This study was designed to evaluate the superiority of itraconazole tablets to placebo tablets. Clinical Cure was defined as an IGA score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) exam and a negative culture for dermatophytes of the target toenail.

Time frame:
1 year
Reported as:
Number · Percentage of participants
Clinical and Mycological Cure of Target Toenail
Percentage of participantsItraconazole TabletsPlacebo Tablets
Clinical and Mycological Cure of Target Toenail22.31
Statistical analysis
  • Itraconazole Tablets vs Placebo Tablets · Cochran-Mantel-Haenszel · p = <0.001This was stratified by analysis center.
PrimaryComplete Cure - Itraconazole Tablets Compared to Itraconazole Capsules

The primary efficacy endpoint was Compete Cure (consisting of a Clinical Cure and a Mycological Cure) at week 52. In this study, Clinical Cure was defined as an Investigator's Global Assessment (IGA) score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) examination and a negative culture outcome for dermatophytes of the target toenail. The efficacy analyses were conducted to demonstrate the non-inferiority of 1 itraconazole 200-mg tablet to 2 itraconazole 100-mg capsule.

Time frame:
12 months
Reported as:
Number · Percentage of participants
Complete Cure - Itraconazole Tablets Compared to Itraconazole Capsules
Percentage of participantsItraconazole TabletsItraconazole CapsulesPlacebo Tablets
Complete Cure - Itraconazole Tablets Compared to Itraconazole Capsules22.321.71.0
Statistical analysis
  • Itraconazole Tablets vs Itraconazole Capsules · Wald's CI · Wald's ci: 0.56The statistical analysis used Wald's CI with Yates' continuity correction.
SecondaryClinical Improvement of the Target Toenail

Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52. The Investigator's Global Assessment (IGA) assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement. 0 = Clinical Cure: No evidence of onychomycosis. 1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: \>50% dystrophy with onycholysis.

Time frame:
12 months
Reported as:
Number · percentage of participants
Clinical Improvement of the Target Toenail
percentage of participantsItraconazole TabletsItraconazole Capsules
Clinical Improvement of the Target Toenail33.729.3
Statistical analysis
  • Itraconazole Tablets vs Itraconazole Capsules · Wald's CI · p = < 0.001 · Mean difference (final values): 10The statistical analysis used Wald's CI with Yates' continuity correction.
SecondaryClinical Improvement Compared to Placebo

Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52. The Investigator's Global Assessment(IGA)assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement. 0 = Clinical Cure: No evidence of onychomycosis. 1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: \>50% dystrophy with onycholysis.

Time frame:
12 months
Reported as:
Number · percentage of participants
Clinical Improvement Compared to Placebo
percentage of participantsItraconazole TabletsPlacebo Tablets
Clinical Improvement Compared to Placebo33.72
Statistical analysis
  • Itraconazole Tablets vs Placebo Tablets · Cochran-Mantel-Haenszel · p = <0.001This was stratified by analysis center.

Adverse events

Collected over AEs and SAES are reported for the 12 week treatment period. SAEs are reported for both the treatment & follow-up periods in the Additional Description section.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Itraconazole Tablets - Treatment Period—2/582 (0.3%)19/582 (3.3%)
Itraconazole Capsules—2/581 (0.3%)16/581 (2.8%)
Placebo Tablets—2/191 (1%)6/191 (3.1%)
Itraconazole Tablets - Follow-up Period—10/535 (1.9%)19/535 (3.6%)
Itraconazole Capsules - Follow-up Period—9/515 (1.7%)36/515 (7%)
Placebo Tablets - Follow-up Period—1/168 (0.6%)8/168 (4.8%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventItraconazole Tablets - Treatment PeriodItraconazole CapsulesPlacebo TabletsItraconazole Tablets - Follow-up PeriodItraconazole Capsules - Follow-up PeriodPlacebo Tablets - Follow-up Period
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5820/5810/1910/5350/5151/168
DiverticulitisInfections and infestations0/5820/5811/1910/5350/5150/168
PancreatitisGastrointestinal disorders0/5820/5811/1910/5350/5150/168
AnemiaBlood and lymphatic system disorders0/5820/5810/1910/5351/5150/168
AppendicitisInfections and infestations0/5820/5810/1911/5351/5150/168
Calculus uretericRenal and urinary disorders0/5820/5810/1910/5351/5150/168
Cerebrovascular accidentNervous system disorders0/5820/5810/1910/5351/5150/168
CholelithiasisHepatobiliary disorders1/5820/5810/1910/5351/5150/168
Cardiac failure congestiveCardiac disorders0/5820/5810/1910/5351/5150/168
Gastric ulcer haemorrhageGastrointestinal disorders0/5820/5810/1910/5351/5150/168
Most frequent other events
Most frequent other events
EventItraconazole Tablets - Treatment PeriodItraconazole CapsulesPlacebo TabletsItraconazole Tablets - Follow-up PeriodItraconazole Capsules - Follow-up PeriodPlacebo Tablets - Follow-up Period
HypoacusisEar and labyrinth disorders19/58216/5816/19119/53536/5158/168

Baseline characteristics

Age, Continuous
Age, Continuous(years)Itraconazole TabletsItraconazole CapsulesPlacebo TabletsTotal
Mean47.1 ± 11.8647 ± 12.6749.2 ± 11.1247.4 ± 12.13
Gender
Gender(Participants)Itraconazole TabletsItraconazole CapsulesPlacebo TabletsTotal
Female4414401531034
Male15215045347
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Itraconazole TabletsItraconazole CapsulesPlacebo TabletsTotal
American Indian or Alaska Native77418
Asian54211
Native Hawaiian or Other Pacific Islander0101
Black or African American484818114
White5124931691174
Unknown or Not Reported2541773
Region of Enrollment
Region of Enrollment(participants)Itraconazole TabletsItraconazole CapsulesPlacebo TabletsTotal
Panama99321
United States5275231761226
Canada2321852
Ecuador68317
Honduras99321
Dominican Republic79218
South Africa1211326
08

Study locations

68 sites
  • Radiant Research -Birmingham
    Birmingham, Alabama 35209, United States
  • University of Alabama School of Medicine
    Birmingham, Alabama 35233, United States
  • Radiant Research - Tucson
    Tuscon, Arizona 85710, United States
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • East Bay Dermatology Medical Group Inc.
    Fremont, California 94538, United States
  • Skin Surgey Medical Group
    San Diego, California 92117, United States
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • University of California
    San Francisco, California 94143-0517, United States
  • Radiant Research - Santa Rosa
    Santa Rosa, California 95405, United States
  • Meridian Skincare
    Englewood, Colorado 80112, United States
  • The Savin Center
    New Haven, Connecticut 06511, United States
  • Dr. Stephen Horwitz
    Aventure, Florida 33180, United States
  • International Dermatology Research Inc.
    Miami, Florida 33144, United States
  • FMX Research Corporation
    Miami, Florida 33175, United States
  • Advanced Dermatology and Cosmetic Surgery
    Ormond Beach, Florida 32174, United States
  • Radiant Research - St. Petersburg
    St. Petersburg, Florida 33781, United States
  • Radiant Research - West Palm Beach
    West Palm Beach, Florida 33407, United States
  • Radiant Research - Atlanta West
    Austell, Georgia 30106, United States
  • Gwinnett Clinical Research Center Inc.
    Snellville, Georgia 30078, United States
  • Northwest Clinical Trials
    Boise, Idaho 83704, United States
  • Radiant Research - Chicago
    Chicago, Illinois 60610, United States
  • Radiant Research - Kansas City
    Overland Park, Kansas 66215, United States
  • Dr. David Fivenson
    Ann Arbour, Michigan 48103, United States
  • Skin and Vein Center
    Troy, Michigan 48083, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • VA Medical Center
    Minneapolis, Minnesota 55417, United States
  • Dr. Eduardo Tschen
    Albuquerque, New Mexico 87106, United States
  • Skin Specialty Group
    New York, New York 10021, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Dermatology Consulting Services
    High Point, North Carolina 27262, United States
  • Dermatology Clinical Research Center
    Cincinnati, Ohio 45219, United States
  • Radiant Research - Cincinnati
    Cincinnati, Ohio 45249, United States
  • Northwest Cutaneous Research
    Portland, Oregon 97210, United States
  • Oregon Medical Research Center
    Portland, Oregon 97223, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Radiant Research - Anderson
    Anderson, South Carolina 29621, United States
  • Radiant Research - Greenville
    Greenville, South Carolina 29617, United States
  • Dr. J. M. Humeniuk
    Greer, South Carolina 29651, United States
  • Dermatology East
    Germantown, Tennessee 38138, United States
  • Dermatology Associates of Knoxville
    Knoxville, Tennessee 37917, United States
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215, United States
  • DermResearch Inc.
    Austin, Texas 78759, United States
  • Dr. Terry Jones
    Bryan, Texas 77802, United States
  • Radiant Research - Dallas North
    Dallas, Texas 75231, United States
  • Dr. Stephen Miller
    San Antoinio, Texas 78229, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78229, United States
  • Dermatology Research Center
    Salt Lake City, Utah 84124, United States
  • South Valley Dermatology Center
    West Jordan, Utah 84088, United States
  • Pariser Dermatology Specialists Ltd.
    Norfolk, Virginia 235507, United States
  • Radiant Research - Tacoma
    Tacoma, Washington 98499, United States
  • Madison Skin and Research Inc.
    Madison, Wisconsin 53719, United States
  • Advanced Healthcare S. C.
    Milwaukee, Wisconsin 53209, United States
  • Dr. Kirk Barber
    Calgary, Alberta T2S3B3, Canada
  • Dr. Richard Thomas
    Vancouver, British Columbia V5Z3Y1, Canada
  • Dr. Marc Bourcier
    Moncton, New Brunswick E1C8X3, Canada
  • Dr. Aditja Gupta
    London, Ontario N5X2P1, Canada
  • Dr. Chuck Lynde
    Markham, Ontario L3P7N8, Canada
  • EntraLogix
    Oakville, Ontario L6K1E1, Canada
  • Dr. Jerry Tan
    Windsor, Ontario N8W5L7, Canada
  • Dr. Robert Bissonnette
    Montreal, Quebec H2K4L5, Canada
  • Edifico Professional Guarionex Lopez
    Santo Domingo, Dominican Republic
  • Dr. Manuel Briones
    Guayaquil, Ecuador
  • Centro Orquidea Blanca
    San Pedro, Sula, Honduras
  • Clinica Metropolis II
    Panama City, Panama
  • Langeberg Medical Centre
    Cape Town, South Africa
  • University of Cape Town
    Cape Town, South Africa
  • Dr. Z. F. Ahmed Vawda
    Durban, South Africa
  • DJW Navorsing
    Krugerson, South Africa
09

References and documents

Publications

  • Maddin S, Quiring J, Bulger L. Randomized, placebo-controlled, phase 3 study of itraconazole for the treatment of onychomycosis. J Drugs Dermatol. 2013 Jul 1;12(7):758-63. PubMed 23884486 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2006
First posted
Jul 27, 2006
Start
Jul 2006
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Jan 4, 2012
Last update
Feb 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00356915
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 27, 2006
Start date
Jul 2006
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Jan 4, 2012
Last update
Feb 9, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itraconazole

Start the discussion